Background Activation of the intrarenal renin-angiotensin system (RAS) plays a critical role in the pathophysiology of chronic kidney disease (CKD) and hypertension. It has been reported that reactive oxygen species (ROS) are important components of intrarenal RAS activation. Melatonin is recognized as a powerful antioxidant, and we recently reported that impaired nighttime melatonin secretion correlates negatively with urinary angiotensinogen excretion, the surrogate marker of intrarenal RAS activity in patients with CKD. However, whether melatonin supplementation ameliorates the augmentation of intrarenal RAS in CKD has remained unknown. We aimed to clarify whether exogenous melatonin ameliorates intrarenal RAS activation via the reduction of ROS production. Methods 5/6 Nephrectomized (Nx) rats were used as a chronic progressive CKD model and compared with shamoperated control rats. The Nx rats were divided into untreated Nx rats and melatonin-treated Nx rats. The levels of intrarenal RAS, ROS components, and renal injury were evaluated after 4 weeks of treatment.
Introduction
The intrarenal renin-angiotensin system (RAS) induces local inflammation and fibrosis, playing a critical role in the pathophysiology of chronic kidney disease (CKD) and hypertension [1, 2] . Inhibition of the intrarenal RAS is crucial in the treatment of CKD. Although the use of RAS blockers including angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II (AngII) type 1 receptor (AT1) blockers has been established in the treatment of CKD, additional agents have remained under investigation.
In both animal and human studies, it has been reported that reactive oxygen species (ROS) are important for intrarenal RAS activation in the progression of CKD [3] [4] [5] . Levels of ROS are known to increase during early-stage CKD, and some in vivo studies have shown that the Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10157-017-1505-7) contains supplementary material, which is available to authorized users. administration of antioxidants, such as tempol, a superoxide dismutase-mimetic drug [6, 7] and hydrogen sulfide [8] , suppresses ROS production and attenuates intrarenal RAS activity in CKD models. These studies indicate that targeting ROS may be a therapeutic intervention strategy to inhibit the intrarenal RAS in CKD.
Melatonin is a hormone produced by the pineal gland, predominantly at night, which is believed to play a major role in regulating the circadian rhythm of several biological systems. Melatonin not only regulates the biological circadian clock, but also serves a variety of biological functions, including anti-inflammation, anti-oxidation, inhibition of sympathetic nerve activity, and preservation of endothelial cell function [9] . Its effects upon the kidney have been proven in several experimental models such as 5/6 nephrectomy rats [10] , unilateral ureteral obstruction rats [11] , spontaneously hypertensive rats [12] , and adriamycin-induced nephropathy [13] by lowering hypertension, retarding deterioration of renal function, and ameliorating its structure mainly by reducing intrarenal ROS generation. Although these findings in animal models indicate that melatonin seems to work through multiple pathways to prevent renal damage, the potential effect of suppressing intrarenal RAS activity has not been reported. In our previous study, the first to demonstrate the contribution of melatonin to intrarenal RAS activation, we found that impaired nighttime melatonin secretion correlates negatively with urinary angiotensinogen (AGT), the surrogate marker of intrarenal RAS activity in patients with CKD [14] . Additionally, Koch et al. have reported that nocturnal melatonin secretion is dramatically reduced in patients with CKD with advancing renal dysfunction [15] . These findings indicate that restoring melatonin levels may retard intrarenal RAS activation by reducing intrarenal oxidative stress. The present study was performed to address the hypothesis that exogenous melatonin counteracts the inappropriate augmentation of the intrarenal RAS in an experimental CKD model.
Materials and methods

Experimental design
Eight-week-old male Sprague-Dawley rats weighing 250-300 g were purchased from SLC (Hamamatsu, Japan) and kept under a 12:12-h light-dark cycle (lights were turned on at 7 am). The rats were subjected to either surgical renal ablation or sham operations. The renal ablation was performed by right nephrectomy followed by surgical resection of the upper and lower thirds of the left kidney 7 days later. The sham operation was conducted without removing the kidney. The excised sections of the left and right kidneys were weighed immediately after removal [10] . Rats surviving for 7 days after the second operation were randomly assigned to the following experimental groups.
Control group (n = 4): rats were subjected to sham operation and were provided with standard food and water.
Nx group (n = 8): rats were subjected to renal ablation and were provided with standard food and drinking water.
Nx ? MEL group (n = 8): rats were subjected to renal ablation and were provided with standard food and melatonin added to the drinking water. Melatonin (SigmaAldrich, MO, USA) was administered in the drinking water (10 mg/100 mL) in containers wrapped in aluminum foil to avoid degradation of the melatonin by light, as previously described [10] .
Animals were euthanized by decapitation 4 weeks after randomization. Urine samples were collected using metabolic cages for 24 h, and BP was measured using a noninvasive tail-cuff method (BP 98A; Softron, Tokyo, Japan) before euthanasia. The blood samples and kidneys were collected immediately after decapitation. One part of the kidney tissue was fixed in 4% paraformaldehyde in phosphate-buffered saline and embedded in paraffin for histopathological evaluation. The rest of the kidney tissue was frozen and stored at -80°C until analysis.
Measurement of renal function and urinary protein excretion
Serum and urinary creatinine (Cr) concentrations were measured by enzymatic assays (Falco SD, Kyoto, Japan). Cr clearance was calculated as previously described [16] . Urinary protein excretion was measured using a pyrogallol red-molybdate protein assay kit (Wako, Osaka, Japan).
Measurement of melatonin and melatonin metabolite
Plasma melatonin concentrations were measured by radioimmunoassay (RIA) (SRL, Tokyo, Japan). Urinary excretion levels of 6-sulphatoxymelatonin (U-aMT6s) were measured by enzyme-linked immunosorbent assay (ELISA) (IBL, Takasaki, Japan). U-aMT6s is the main metabolite of melatonin, and its urinary excretion levels closely correlates with the total level of melatonin in the plasma during the collection period [17] .
Measurement of circulating RAS concentrations and urinary AGT excretion levels
Plasma AngII levels were measured by RIA (SRL) to evaluate the circulating RAS concentrations [18] . In addition, levels of urinary AGT, as a surrogate marker of intrarenal RAS activity were measured by ELISA (IBL) as previously described [19] .
Immunoblot analysis of intrarenal RAS components
To evaluate the intrarenal RAS components, immunoblot analysis of AGT and AT1R was conducted as previously described [20] . The primary antibodies were rabbit anti-AGT antibody (IBL) and rabbit anti-AT1R antibody (Santa Cruz Biotechnology, CA, USA). Mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology) was also used. The accumulation of these proteins as determined by immunoblot analysis was normalized against that of GAPDH.
Measurement of intrarenal AngII concentrations
AngII levels in the whole kidney were measured by RIA (SRL), according to the manufacturer's instructions. Intrarenal AngII concentrations were normalized against the weight of the resected kidney fragment as previously described [21] .
Immunohistochemical analysis
Kidney samples were sectioned at 3-lm intervals and immunostaining for AGT, AngII, a-smooth muscle actin (a-SMA), Snail, melatonin type 1 receptor A (Mel1A), and 8-hydroxy-2 0 -deoxyguanosine (8-OHdG) was conducted using a Histofine kit (Nichirei-Bioscience, Tokyo, Japan) as previously described [22, 23] . The primary antibodies were the rabbit anti-AGT antibody (IBL), rabbit anti-AngII antibody (Phoenix Pharmaceuticals, Burlingame, CA, USA), mouse anti-a-SMA antibody (Dako, Glostrup, Denmark), rabbit anti-Snail antibody (Abcam, Cambridge, UK), rabbit anti-Mel1A antibody (Abcam), and mouse anti-8-OHdG antibody (Japan Institute for control of Aging, Shizuoka, Japan). The immunoreactivity of AGT, AngII, a-SMA, Snail, and Mel1A was quantitatively evaluated by a semi-automatic image analysis system using Image Pro Plus software (Media Cybernetics, GA, USA) [6, 18, 22, [24] [25] [26] . Random 20 microscopic fields (4009) in the renal cortex were examined for each experimental animal, and the averages of AGT, AngII, a-SMA, Snail, and Mel1A-positive areas, excluding vascular and glomerular lesions, were obtained. The number of 8-OHdG-positive nuclei was counted in random 20 fields (4009) in each experimental animal and its average value was calculated. The picrosirius-red method was used to stain type I collagen in a kidney section using a commercially available kit (Polysciences, Inc., PA, USA). The immunoreactivity of the type I collagen was quantitatively evaluated using a semi-automatic image analysis system as described above.
Renal superoxide dismutase activity
Superoxide dismutase (SOD) activity in the whole kidney was measured using a commercially available kit (Dojindo Molecular Technologies, Kumamoto, Japan) as previously described [27] .
Measurement of renal norepinephrine concentrations
Concentrations of norepinephrine in renal homogenates were measured by ELISA (Abnova, Taipei, Taiwan) according to the manufacturer's protocol [28] .
Statistical analysis
Results were expressed as mean ± SE. Significant differences among the groups were determined using analysis of variance followed by Tukey's or Games-Howell's post hoc analysis, as appropriate. Logarithmic transformation was used for urinary AGT/creatinine (AGT/Cr) ratios because they were not normally distributed [29] . The correlation between the urinary AGT/Cr levels and the immunoreactivity of AGT was evaluated using Pearson's product-moment correlation coefficient. A P value of \ 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software, version 21 (SPSS, Chicago, IL, USA).
Results
General data
The mean left/right weight ratios of the removed kidneys were not different between the Nx and the Nx ? MEL groups (Nx group: 0.67 ± 0.05, Nx ? MEL group: 0.71 ± 0.04; P = 0.64), demonstrating that surgical renal ablation was performed equivalently between the groups.
General data obtained before sacrifice is summarized in Table 1 . Body weight in the control group was significantly greater than that in the other groups, and body weight in the Nx ? MEL group tended to be greater compared with that of the Nx group. However, no significant differences were found between the groups. Renal ablation induced significant hypertension in both the Nx and the Nx ? MEL groups, and systolic blood pressure was then significantly lowered by the melatonin treatment. The Nx group also exhibited significant proteinuria, increased blood urea nitrogen and serum creatinine, and reduced creatinine clearance compared with the control group. Although the difference did not achieve statistical significance, the melatonin treatment showed a tendency to improve proteinuria and renal function compared with results of the untreated Nx group. In the Nx group, plasma AngII was decreased compared with the control group, probably due to suppression by fluid retention. However, there were no significant differences in plasma AngII between the Nx group and the Nx ? MEL group. The plasma melatonin concentration at 2 am, and the levels of U-aMT6s excretion in whole day, were extremely high in the Nx ? MEL group compared to the control and the Nx groups. Plasma melatonin concentrations in the Nx group tended to be lower than those in the control group, and the U-aMT6s excretion levels in the Nx group were significantly lower than those in the control group. U-aMT6s excretion levels peaked between 2 am and 8 am in the control and the Nx ? MEL groups, however, no obvious surge in the overnight excretion of U-aMT6s was observed in the Nx group (Supplemental Fig. 1 ).
Melatonin receptor in kidney
Immunostaining for Mel1A revealed expressions in both the proximal and the distal tubules, but not in the glomeruli. No differences in staining were observed among the groups (Fig. 1) .
Intrarenal oxidative stress levels
Antioxidant and oxidative stress status was evaluated by determining SOD activity and 8-OHdG-positive cells in the remnant kidney. Renal SOD activity was significantly reduced in the Nx group compared with the control group, which was subsequently reversed by melatonin treatment in the Nx ? MEL group (Fig. 2a) . In normal kidneys, 8-OHdG was rarely detected in the cortical tubular cells, whereas significant staining in the nuclei of damaged cortical tubular cells was observed in the Nx group, and the numbers of 8-OHdG-positive cells were significantly decreased in the Nx ? MEL group (Fig. 2b) . On the other hand, the levels of norepinephrine in the kidney were not significantly different among the groups (control group: 249.6 ± 0.61 pg/mg protein, Nx group: 197.0 ± 2.86 pg/ mg protein and Nx ? MEL group: 165.5 ± 2.43 pg/mg protein, respectively).
Intrarenal RAS activity
We evaluated AGT, AT1R, and AngII to determine the intrarenal RAS components. The levels of urinary AGT/Cr in the Nx group were considerably higher than those in the control group. Melatonin treatment significantly decreased the levels of urinary AGT/Cr (Fig. 3c) , and immunostaining for AGT protein expression confirmed the finding. Namely, immunostaining for AGT revealed slight expression in the proximal tubular cells in the control group and dramatically increased expression in the Nx group. Melatonin significantly attenuated the expression of AGT compared with that in the Nx group (Fig. 3b) . Although it did not reach statistical significance, immunoblot analysis for AGT protein expression revealed a similar result (P = 0.08; Fig. 3a ). Significant correlation was observed between the urinary AGT/Cr levels and the immunostaining for AGT expression levels (r = 0.58, p \ 0.05).
Immunoblot analysis for AT1R revealed significantly higher expression in the Nx group than in the control group, and significantly attenuated expression in the Nx ? MEL group (Fig. 4) .
Immunostaining for AngII was mainly detected in some distal tubular cells in the control group. Immunostaining for AngII in the Nx group revealed significant expression in the proximal and distal tubules, which was significantly reduced in the Nx ? MEL group (Fig. 5) . On the other hand, renal AngII concentration measured by RIA was not significantly different among the groups (control group: 280.8 ± 66.5 pg/g tissue, Nx group: 211.9 ± 22.4 pg/g tissue and Nx ? MEL group: 215.7 ± 12.6 pg/g tissue, respectively). 
Intrarenal fibrotic expression levels
To assess the degree of renal histological injury, the expression of three fibrotic components, a-SMA, Snail and type I collagen, in the remnant kidney was evaluated. Both a-SMA levels and the type I collagen positive area in the interstitial lesion, and Snail positive tubular epithelial cells were significantly increased in the Nx group compared with those in the control group, and these elevations were significantly attenuated in the Nx ? MEL group (Fig. 6 ).
Discussion
Exogenous melatonin successfully ameliorated the renal oxidative stress caused by 5/6 nephrectomy as reflected by increase in SOD activity and decrease in 8-OHdG-positive cells. The important findings of this study demonstrate that melatonin treatment prevented the augmentation of intrarenal RAS components, including AGT, AT1R, and AngII with resultant attenuation of hypertension and renal fibrosis as evaluated by expression of aSMA, Snail, and type I collagen in the 5/6 Nx rats. To our knowledge, this is the first study to provide clear evidence that the administration of melatonin inhibits intrarenal RAS activity in a CKD model.
The renal protective effects of melatonin have been shown in several experimental CKD models and its detailed mechanisms have varied among studies. Melatonin receptors were present in the kidney and the expression levels were the same among the groups. However, it is known that melatonin acts as a scavenger for ROS through non receptor-mediated mechanisms, and can act at both intracellular and nuclear binding sites [30, 31] . Therefore, it is possible that the level of expression of the melatonin receptor did not play a pivotal role in our study. Nava et al. reported that melatonin administration decreased activation of nuclear factor kappa B (NF-jB), likely resulting from a reduction in local oxidative stress in spontaneously hypertensive rats [12] . Ozbek et al. demonstrated that melatonin prevented unilateral ureteral obstruction-induced renal damage by normalizing the levels of malondialdehyde, glutathione, nitric oxide (NO), and 8-OHdG via a reduction in the expression of inducible NO synthase, p38-mitogen-activated protein kinase (p38-MAPK), and NF-jB [11] . The protective effect of melatonin against renal fibrosis via decreased transforming growth factor-b abundance was also reported [32] , thus resulting in preserved renal function and structure [10] . Moreover, melatonin is known to have antihypertensive effects and it plays a role in the inhibition of sympathetic nerve activity, preserving endothelial cell function and stimulating NO synthesis, which results in vasodilatation [9] . These findings suggest that melatonin works through multiple pathways to offset renal damage. Although the underlying molecular mechanism was not fully established in our present study, inhibition of the intrarenal RAS has been suggested as an additional possible renal protective mechanism of melatonin.
Since melatonin demonstrates anti-oxidative properties and plays a role in free radical scavenging as described above, decreased ROS is considered a major factor in the mechanism of controlling intrarenal RAS activation. There is increasing evidence that oxidative stress can regulate intrarenal RAS components. For example, the overexpression of catalase (a scavenger of hydrogen peroxide) in proximal tubule cells was shown to attenuate intrarenal AGT expression in diabetic mice [33] . Catalase overexpression was also shown to prevent hypertension, albuminuria, tubulointerstitial fibrosis, and tubular apoptosis in transgenic mice that overexpress AGT [34] . Abdo et al. investigated the association of AGT gene expression and nuclear factor erythroid 2-related factor 2 (Nrf2; a master regulator of redox balance in cellular cytoprotective responses) in diabetic mice, and they documented that Nrf2 activation by oxidative stress stimulates intrarenal AGT gene expression and RAS activation, subsequently leading to hypertension and the development of nephropathy [35] . Moreover, Cao et al. demonstrated that advanced oxidation protein products (AOPP) up-regulated the expression of intrarenal RAS components, such as mRNA and protein levels of AGT, ACE, AT1R, and AngII, mainly mediated by a CD36-dependent, redox-sensitive signaling involving the activation of protein kinase C, NADPH oxidase, and NF-jB in both in vitro and in vivo studies [36] . These recent experimental findings clearly show that ROS-dependent intrarenal RAS activation plays an important role in the pathogenesis of CKD.
There has been great interest in developing strategies that target the ROS-RAS axis in the treatment of CKD. Luo et al. reported that antioxidant treatment with tempol attenuated oxidative stress, lowered BP, and reversed the imbalance of renal RAS components including ACE, AT1R, AngII type 2 receptors, and Mas receptor mRNA and proteins in obese rats [7] . Similarly, hyperglycemiainduced oxidative stress and intrarenal RAS activity was reportedly reversed by hydrogen sulfide supplementation [8] . These studies support our results that supplementation of melatonin, a powerful antioxidant, reduces intrarenal RAS activation by decreasing ROS production.
Both ROS and activation of the renal sympathetic nervous system initiate activation of intrarenal RAS through the reno-cerebral reflex [28] . Acute administration of melatonin reduced both BP and plasma norepinephrine levels in spontaneously hypertensive rats [37] . Chronic administration of melatonin decreased BP and heart rate, inhibited sympathetic nerve activity, and restored cardiac b-adrenoceptor function [38] . Although the levels of norepinephrine content in the kidney were not significantly different among the groups, renal sympathetic nerve b Fig. 6 Immunostaining for fibrotic changes in the kidney. activity has not been recorded in our study, and attenuation of renal sympathetic nerve tone might have played a role in reducing intrarenal RAS components. Although AGT is generated in the proximal tubules [1] , Matsusaka et al. demonstrated that AGT produced in the liver and filtered through the glomerular basement membrane is the primary source of intrarenal AngII [39] . In our present study, although the difference did not reach statistical significance (primarily due to wide variability in the values found in the groups), proteinuria tended to be lower in the Nx ? MEL group compared with the Nx group. It is possible that AGT excreted from the glomerulus was reduced by melatonin and led to decreased AngII generation. Some studies have revealed melatonin's protective effect from glomerular sclerosis [10] and proteinuria [10, 13] in CKD models. In addition, we previously reported that nighttime endogenous melatonin secretion was associated with not only urinary AGT, but also urinary albumin excretion in patients with CKD [14] . Whether melatonin influences the glomerular permeability of AGT, or the generation of AGT in the proximal tubules, or both, is an interesting question that requires further research.
In the present study, systolic blood pressure was ameliorated in the Nx ? MEL group compared with the Nx group. This may be relevant to both the antihypertensive effect of melatonin and decreased intrarenal RAS components in this group. It is possible that the effects of melatonin on regulating intrarenal RAS activity are dependent on blood pressure changes. However, intrarenal RAS activation causes hypertension [40, 41] , and the lower blood pressure observed in the melatonin treated group, substantially, seems to be the result of reduced intrarenal RAS activity and preserved renal structure. In our previous study with anti-thymocyte serum nephritis rats, treatment with hydralazine (a vasodilator) did not inhibit intrarenal RAS components despite a marked decrease in blood pressure compared with untreated nephritis rats [18] . This result is consistent with previous experimental studies with IgA nephritis [6] and Dahl salt-sensitive rats [42] . Hence, the effects of melatonin on intrarenal RAS activity are not solely the consequence of blood pressure changes.
As a serious limitation in our experiment, renal AngII concentration evaluated by RIA was not significantly different among the groups, and the control group exhibited the highest concentration. The result was inconsistent with other RAS components obtained in our experiment, and thus we determined that this assay did not work properly. Because of its low molecular weight, AngII is known to be an unstable substance and it could have degraded during the assay. Since the evaluation of the AngII positive area is an established method in our and other groups works, and has been accepted in previous reports [18, 25, 26] , we believe that immunostaining for AngII reflects intrarenal RAS activity in this study.
Conclusion
In summary, we conclude that melatonin was shown to prevent the augmentation of intrarenal RAS in a 5/6 Nx model along with decreases in blood pressure, oxidative load, and renal histological injury. The inhibition of intrarenal RAS has been suggested as a possible mechanism in the renal protective role of melatonin.
